JP2012532185A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532185A5
JP2012532185A5 JP2012518956A JP2012518956A JP2012532185A5 JP 2012532185 A5 JP2012532185 A5 JP 2012532185A5 JP 2012518956 A JP2012518956 A JP 2012518956A JP 2012518956 A JP2012518956 A JP 2012518956A JP 2012532185 A5 JP2012532185 A5 JP 2012532185A5
Authority
JP
Japan
Prior art keywords
conjugate
therapeutic agent
asparaginase
peg
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012518956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532185A (ja
JP6014956B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/054156 external-priority patent/WO2011003633A1/en
Application filed filed Critical
Publication of JP2012532185A publication Critical patent/JP2012532185A/ja
Publication of JP2012532185A5 publication Critical patent/JP2012532185A5/ja
Application granted granted Critical
Publication of JP6014956B2 publication Critical patent/JP6014956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012518956A 2009-07-06 2010-07-06 ペグ化されたｌ−アスパラギナーゼ Active JP6014956B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22332009P 2009-07-06 2009-07-06
US61/223,320 2009-07-06
PCT/EP2010/054156 WO2011003633A1 (en) 2009-07-06 2010-03-30 Pegylated l-asparaginase
EPPCT/EP2010/054156 2010-03-30
PCT/EP2010/059599 WO2011003886A1 (en) 2009-07-06 2010-07-06 Pegylated l-asparaginase

Publications (3)

Publication Number Publication Date
JP2012532185A JP2012532185A (ja) 2012-12-13
JP2012532185A5 true JP2012532185A5 (https=) 2013-08-22
JP6014956B2 JP6014956B2 (ja) 2016-10-26

Family

ID=42232655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518956A Active JP6014956B2 (ja) 2009-07-06 2010-07-06 ペグ化されたｌ−アスパラギナーゼ

Country Status (25)

Country Link
US (6) US20120100121A1 (https=)
JP (1) JP6014956B2 (https=)
KR (1) KR101731999B1 (https=)
CN (1) CN102573917B (https=)
AU (1) AU2010270294B2 (https=)
BR (1) BR112012000367A2 (https=)
CA (1) CA2767149C (https=)
CO (1) CO6612174A2 (https=)
DK (1) DK2451486T4 (https=)
EA (1) EA021168B1 (https=)
ES (1) ES2636476T5 (https=)
FI (1) FI2451486T4 (https=)
HU (1) HUE035771T2 (https=)
IL (1) IL217392A (https=)
IN (1) IN2012DN00958A (https=)
LT (1) LT2451486T (https=)
MA (1) MA33503B1 (https=)
MX (1) MX2012000424A (https=)
MY (1) MY180758A (https=)
NZ (1) NZ597912A (https=)
PE (2) PE20120501A1 (https=)
PT (1) PT2451486T (https=)
SG (1) SG176984A1 (https=)
UA (1) UA104634C2 (https=)
WO (2) WO2011003633A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE531779C2 (sv) * 2007-11-26 2009-08-04 Promimic Ab Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015038639A1 (en) * 2013-09-10 2015-03-19 Sandia Corporation Therapeutic asparaginases
CN104046600B (zh) 2013-12-30 2019-04-05 江苏众红生物工程创药研究院有限公司 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用
BR102014000585B1 (pt) 2014-01-10 2021-01-12 Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação l-asparaginase recombinante de zymomonas
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
CN105802948B (zh) 2014-12-29 2020-06-09 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
WO2017055484A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
CA3054286A1 (en) * 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
CN109640961B (zh) 2016-06-01 2021-11-02 施维雅知识产权英国有限公司 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3535386A4 (en) * 2016-11-04 2020-04-15 Georgia State University Research Foundation, Inc. ENDOTOXIN-FREE ASPARAGINASE
SG11201912625QA (en) * 2017-06-21 2020-01-30 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
EP3418383A1 (en) * 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
EP3701036A4 (en) 2017-10-27 2021-09-01 Pfenex Inc. PROCESS FOR PRODUCING ASPARAGINASE OF E. COLI
JP7784804B2 (ja) * 2017-10-27 2025-12-12 フェネックス インク． 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法
CA3240356A1 (en) * 2017-11-30 2019-06-06 Jazz Pharmaceuticals Ireland Ltd. Methods of treatment with asparaginase
JP2021520828A (ja) * 2018-04-19 2021-08-26 キンドレッド バイオサイエンシズ インコーポレイテッド 医療用の変異体アスパラギナーゼポリペプチド
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
PE20220492A1 (es) * 2018-12-24 2022-04-07 Gennova Biopharmaceuticals Ltd Composicion liofilizada de pegaspargasa
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
GB201912020D0 (en) * 2019-08-21 2019-10-02 Porton Biopharma Ltd Therapeutic Conjugate
CA3156066A1 (en) * 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase
KR102269634B1 (ko) * 2019-10-31 2021-06-25 대상 주식회사 ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주
AU2021410080A1 (en) 2020-12-23 2023-06-22 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
CN114854729B (zh) * 2021-02-03 2025-09-02 重庆派金生物科技有限公司 定向化学偶联门冬酰胺酶突变体及其制备方法和应用
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2024008659A1 (en) 2022-07-04 2024-01-11 Institut National de la Santé et de la Recherche Médicale Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma
US20260007728A1 (en) 2022-07-14 2026-01-08 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase
WO2024211977A1 (pt) * 2023-04-12 2024-10-17 Biobreyer Pesquisa E Desenvolvimento Científico Ltda Processo de peguilação sítio específica de lasparaginase contendo cisteínas de superfície, produto obtido por processo e uso

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
AU2002332371A1 (en) * 2001-08-22 2003-03-10 Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
WO2007123006A1 (ja) 2006-04-21 2007-11-01 Konica Minolta Holdings, Inc. ガスバリアフィルム、有機エレクトロルミネッセンス用樹脂基材、それを用いた有機エレクトロルミネッセンス素子及びガスバリアフィルムの製造方法
EP2851424B1 (en) * 2007-03-09 2016-09-21 Novozymes A/S Thermostable asparaginases
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof

Similar Documents

Publication Publication Date Title
JP2012532185A5 (https=)
TWI864472B (zh) 抗體的特異性偶聯
US12611461B2 (en) Bioorthogonal compositions
JP2021505661A5 (https=)
Pasut et al. PEG conjugates in clinical development or use as anticancer agents: an overview
FI2451486T4 (fi) Pegyloitu L-asparaginaasi
JP2024069234A5 (https=)
SI2451486T1 (en) Pegylated L-asparaginase
EP2477641B1 (en) Inhibition of endosomal toll-like receptor activation for treating thrombotic disorders
JP2011006428A5 (https=)
TWI500629B (zh) 介白素－６抗體及其用途
CN113874049A (zh) 用于治疗粘膜癌的单独或与i型ifn诱导剂组合的基于壳聚糖多聚复合物的il-12的局部表达
JP2020520917A5 (https=)
TW201922285A (zh) 降低抗cd30抗體藥物綴合物療法之副作用之方法
JP2018530525A5 (https=)
CA2713571C (en) Pharmaceutical composition or combination drug
US20200392289A1 (en) Biodegradable Polymer and Use Thereof
RU2009122976A (ru) Конъюгат полиэтиленгликоля-г-ксф
EP4644416A3 (en) Interleukin 5 binding protein dosage regimen
AU2006246958A1 (en) Triazine compounds and compositions thereof for the treatment of cancers
EP3368609A1 (en) Multifunctional biodegradable carriers for drug delivery
JP2019505493A5 (https=)
JP2021520344A5 (https=)
HK40118230A (en) Bioorthogonal compositions
NZ768282A (en) Compounds including a mutant kras sequence and a lipid and uses thereof